The American Society of Addiction Medicine released clinical guidance Nov. 10, 2026, on managing medetomidine intoxication and withdrawal. Medetomidine is a veterinary sedative now contaminating the U.S. fentanyl supply, and withdrawal from it is driving ICU admissions.
Here are six things to know:
- The sedative is spreading. Medetomidine appeared nationwide in opioid-positive drug samples by December 2025, according to the National Institute of Standards and Technology. Contamination reaches 90% in some mid-Atlantic supplies.
- ICU demand has surged since medetomidine entered the supply. At Philadelphia-based University of Pennsylvania Health System, the share of admitted emergency department patients with opioid use disorder who needed ICU care and dexmedetomidine rose from 5.7% before medetomidine became prevalent to 31.7% after. At Philadelphia-based Jefferson Health, median quarterly ICU admissions for opioid withdrawal climbed from 18 when fentanyl alone dominated the supply to 64 after medetomidine emerged.
- Standard treatments fall short. Naloxone is still needed to restore breathing because nearly all patients are also exposed to fentanyl, but it does not reverse medetomidine sedation. Benzodiazepines, phenobarbital and full opioid agonists do not control the withdrawal, which in extreme cases can push heart rates above 170 beats per minute within hours of last use.
- Pharmacy and formulary teams need to plan. Alpha-2 agonists such as clonidine and dexmedetomidine anchor treatment, often at doses far above typical limits.
- Coding gaps hide the true burden. ASAM said medetomidine withdrawal has no specific diagnostic code, so its incidence remains unknown. ASAM called for consistent coding, specialized intermediate care units and billing models that cover the complex care these patients need.
- Care continues after discharge. Many patients need alpha-2 agonist tapers lasting weeks to months. ASAM recommends Level 3.7 medically managed residential treatment for patients stabilized in the hospital.
ASAM said the recommendations rest largely on inpatient experience and will likely evolve as evidence on the syndrome builds.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
